Dowlati Lead Investigator on Successful Completion of Phase I Safety Trial of Cancer Drug RH324

In collaboration with Case CCC's consortium partners University Hospitals and Case Western Reserve University, ReHeva Biosciences, a pharmaceutical startup specializing in naturally derived complex cancer therapies, and Phase 1 Safety Trial Principal Investigator Afshin Dowlati, MD, Case CCC's Associate Director for Clinical Research and a member of the Developmental Therapeutics Program, have successfully completed the trial for the novel drug RH324.

Receiving the FDA Investigational New Drug (IND) allowance in 2018 paved the way for ReHeva's Phase I Safety Study in advanced NSCLC patients designed to assess the safety and tolerability of RH324.

"Partnering with ReHeva Biosciences to evaluate the use of RH324 could provide patients with another treatment option for cancer with less toxicity," Dowlati explained. Completion of the Phase 1 Safety and Tolerability trial means that future Phase 2 trials can address multiple cancer types.

Read More